Form 4: Lifecore Biomedical Executive Adjusts Holdings

Lifecore Biomedical's CEO, Paul Josephs, reported a transaction involving common stock, impacting his beneficial ownership.

Summary

• Paul Josephs, Chief Executive Officer and Director of Lifecore Biomedical, Inc., reported a transaction on May 20, 2026.
• This transaction involved 40,413 shares of common stock.
• The shares were acquired at a price of $4.57, with the transaction code 'F' indicating a disposition.
• Following this transaction, Josephs beneficially owns 592,915 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard insider transaction disclosure without immediate implications for the company's financial performance or strategic direction.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive holdings and activities. This specific filing details a disposition of shares by a key executive, which can be a routine event related to compensation or personal financial management.

Stakeholder Impact

• Shareholders: The transaction provides transparency into executive stock holdings, which is a standard part of corporate governance. The disposition of shares by the CEO may be interpreted in various ways, but without further context, it is considered a routine event.

Key Dates

Keywords

Lifecore Biomedical, Form 4, SEC Filing, Insider Transaction, Common Stock, Beneficial Ownership, Paul Josephs, CEO, Director